Drug Type Small molecule drug |
Synonyms GST HG141, GST-HG141 |
Action modulators, inhibitors |
Mechanism HBV core protein modulators, cccDNA inhibitors(covalently closed circular DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC19H21N3O6S |
InChIKeyOXJNOWPZKFUKNS-AWEZNQCLSA-N |
CAS Registry2243162-66-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 3 | China | 23 Jul 2025 |
Phase 1 | Hepatitis B, Chronic HBV DNA | pregenomic RNA (pgRNA) | - | GST-HG141 25 mg | wdekfoaejh(ajfbwlxucs) = three cases of grade 1 transaminase elevations yrffexpepi (uinrykyihe ) View more | Positive | 20 Dec 2024 | |
GST-HG141 100 mg | |||||||
Phase 1 | - | ythagttpfj(jhetmfslqe) = ctpsqrfvko fjgrxwubhi (tpcbokmotj ) | Positive | 25 Jun 2022 | |||
ythagttpfj(jhetmfslqe) = vndhoorphe fjgrxwubhi (tpcbokmotj ) | |||||||
Phase 1 | - | kjstojjiyf(attokmeyeo) = yjjxjvgddp vnyixnsxmb (qqbrtyobsl, 3.65) View more | - | 23 Jun 2021 |